Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.

Castle Biosciences, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

FRIENDSWOOD, TEXAS, JULY 22, 2026 /PRNEWSWIRE/ -- CASTLE BIOSCIENCES, INC.(NASDAQ: CSTL), A COMPANY IMPROVING HEALTH THROUGH INNOVATIVE TESTS THAT GUIDE PATIENT CARE, TODAY ANNOUNCED THAT ITS EXECUTIVE MANAGEMENT IS SCHEDULED TO PRESENT A COMPANY OVERVIEW AT THE CANACCORD GENUITY 46THANNUAL GROWTH CONFERENCE ON WEDNESDAY, AUG. 12, 2026, AT 11:30 A.M. EASTERN TIME.

CASTLE BIOSCIENCES TO PRESENT AT THE CANACCORD GENUITY 46TH ANNUAL GROWTH CONFERENCE

APPROVAL EXPANDS ACCESS TO CASTLE'S PRECISION MEDICINE TEST DESIGNED TO GUIDE SYSTEMIC TREATMENT DECISION MAKING IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS FRIENDSWOOD, TEXAS, JULY 14, 2026 /PRNEWSWIRE/ -- CASTLE BIOSCIENCES, INC. (NASDAQ: CSTL), A COMPANY IMPROVING HEALTH THROUGH INNOVATIVE TESTS THAT GUIDE PATIENT CARE, TODAY ANNOUNCED THAT IT HAS RECEIVED ASSAY APPROVAL FROM THE NEW YORK STATE DEPARTMENT OF HEALTH (NYSDOH) FOR ITS ADVANCEAD-TX TEST. ADVANCEAD-TX IS A NON-INVASIVE GENE EXPRESSION PROFILE TEST DESIGNED TO GUIDE SYSTEMIC THERAPY SELECTION FOR PATIENTS AGED 12 YEARS AND OLDER WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS (AD).

CASTLE BIOSCIENCES ANNOUNCES NEW YORK STATE DEPARTMENT OF HEALTH APPROVAL OF ITS ADVANCEAD-TX TEST

FRIENDSWOOD, TEXAS, JULY 9, 2026 /PRNEWSWIRE/ -- CASTLE BIOSCIENCES, INC. (NASDAQ: CSTL), A COMPANY IMPROVING HEALTH THROUGH INNOVATIVE TESTS THAT GUIDE PATIENT CARE, TODAY ANNOUNCED THAT IT WILL RELEASE ITS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026, AFTER THE CLOSE OF MARKET ON THURSDAY, JULY 30, 2026. COMPANY MANAGEMENT WILL HOST A WEBCAST TO DISCUSS ITS FINANCIAL RESULTS AT 4:30 P.M.

CASTLE BIOSCIENCES TO RELEASE SECOND QUARTER 2026 FINANCIAL RESULTS AND HOST WEBCAST ON THURSDAY, JULY 30, 2026

NEWLY PUBLISHED PROSPECTIVE STUDY SHOWS DECISIONDX-MELANOMA'S I31-SLNB TEST RESULT MORE ACCURATELY IDENTIFIES PATIENTS AT LOW AND HIGH RISK OF SENTINEL LYMPH NODE (SLN) POSITIVITY THAN THE MELANOMA INSTITUTE AUSTRALIA (MIA) NOMOGRAM PATIENTS CLASSIFIED AS LOW RISK BY THE I31-SLNB RESULT HAD A 2.6% OBSERVED SLN POSITIVITY RATE, FALLING WELL BELOW THE NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) 5% THRESHOLD USED TO CONSIDER AVOIDING SENTINEL LYMPH NODE BIOPSY (SLNB), COMPARED WITH A 5.8% OBSERVED POSITIVITY RATE FOR THE MIA NOMOGRAM FRIENDSWOOD, TEXAS, JUNE 25, 2026 /PRNEWSWIRE/ -- CASTLE BIOSCIENCES, INC. (NASDAQ: CSTL), A COMPANY IMPROVING HEALTH THROUGH INNOVATIVE TESTS THAT GUIDE PATIENT CARE, TODAY ANNOUNCED THE PUBLICATION OF A PROSPECTIVE, MULTICENTER STUDY IN DERMATOLOGY AND THERAPY DEMONSTRATING THAT DECISIONDX-MELANOMA'S INTEGRATED SENTINEL LYMPH NODE BIOPSY TEST RESULT (I31-SLNB) OUTPERFORMS THE MIA NOMOGRAM IN IDENTIFYING PATIENTS AT LOW AND HIGH RISK OF SLN POSITIVITY, SUPPORTING MORE INFORMED SLNB DECISION-MAKING FOR PATIENTS WITH CUTANEOUS MELANOMA (CM).1 THIS IS THE SECOND MULTICENTER STUDY SHOWING THAT THE I31-SLNB RESULT OUTPERFORMS THE MIA NOMOGRAM IN ASSESSING SLN POSITIVITY RISK.2 "MANY CLINICIANS ARE FAMILIAR WITH NOMOGRAMS THAT ESTIMATE RISK OF SENTINEL LYMPH NODE POSITIVITY USING CLINICOPATHOLOGIC FEATURES ALONE, YET CURRENT GUIDELINES ACKNOWLEDGE LIMITATIONS IN THEIR PERFORMANCE AT LOWER RISK THRESHOLDS," SAID ROHIT SHARMA, M.D., FACS, LEAD AUTHOR OF THE STUDY AND SURGICAL ONCOLOGIST AT MARSHFIELD CLINIC HEALTH SYSTEM IN MARSHFIELD, WISCONSIN.

DECISIONDX-MELANOMA'S I31-SLNB OUTPERFORMS MIA NOMOGRAM IN IDENTIFYING PATIENTS WHO MAY SAFELY FORGO SENTINEL LYMPH NODE BIOPSY

STOKES WAS ONE OF 22 FINANCIAL LEADERS RECOGNIZED IN THE GREATER HOUSTON AREA FRIENDSWOOD, TEXAS, JUNE 23, 2026 /PRNEWSWIRE/ -- CASTLE BIOSCIENCES, INC. (NASDAQ: CSTL), A COMPANY IMPROVING HEALTH THROUGH INNOVATIVE TESTS THAT GUIDE PATIENT CARE, TODAY ANNOUNCED THAT FRANK STOKES, ITS CHIEF FINANCIAL OFFICER, HAS BEEN NAMED A 2026 CFO AWARDS HONOREE BY THE HOUSTON BUSINESS JOURNAL. STOKES IS AMONG 22 CHIEF FINANCIAL OFFICERS FROM ACROSS THE GREATER HOUSTON AREA RECOGNIZED FOR THEIR FINANCIAL LEADERSHIP AND CONTRIBUTIONS TO THEIR ORGANIZATIONS' SUCCESS.

CASTLE BIOSCIENCES' CHIEF FINANCIAL OFFICER FRANK STOKES NAMED A 2026 CFO AWARDS HONOREE BY THE HOUSTON BUSINESS JOURNAL

FRIENDSWOOD, TEXAS, JUNE 19, 2026 /PRNEWSWIRE/ -- CASTLE BIOSCIENCES, INC. (NASDAQ: CSTL), A COMPANY IMPROVING HEALTH THROUGH INNOVATIVE TESTS THAT GUIDE PATIENT CARE, TODAY ANNOUNCED THAT ON JUNE 15, 2026, THE COMPENSATION COMMITTEE OF ITS BOARD OF DIRECTORS GRANTED RESTRICTED STOCK UNITS (RSUS) TO 172 EMPLOYEES COVERING AN AGGREGATE OF 204,925 SHARES OF COMMON STOCK AS AN INDUCEMENT MATERIAL TO THEIR ENTERING INTO EMPLOYMENT WITH CASTLE BIOSCIENCES. THE RSUS WERE GRANTED PURSUANT TO THE COMPANY'S 2022 INDUCEMENT PLAN IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

CASTLE BIOSCIENCES REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

STOCKHOLM, JUNE 10, 2026 /PRNEWSWIRE/ --SCIBASE HOLDING AB ("SCIBASE") (STO: SCIB), A LEADING DEVELOPER OF AI-POWERED SKIN HEALTH SOLUTIONS, TODAY ANNOUNCED THAT THE FIRST PATIENT HAS BEEN ENROLLED IN A NEW STUDY TO ASSESS FLARE PREDICTION IN ATOPIC DERMATITIS. THE PRIMARY OBJECTIVE OF THE MULTICENTER PROSPECTIVE CLINICAL STUDY IS TO ASSESS THE PREDICTION OF FLARES IN ATOPIC DERMATITIS (AD).

FIRST PATIENT ENROLLED IN NEW STUDY ASSESSING EARLY PREDICTION OF FLARES IN ATOPIC DERMATITIS BY CASTLE BIOSCIENCES IN COLLABORATION WITH SCIBASE

FRIENDSWOOD, TEXAS, MAY 13, 2026 /PRNEWSWIRE/ --CASTLE BIOSCIENCES, INC.(NASDAQ: CSTL), A COMPANY IMPROVING HEALTH THROUGH INNOVATIVE TESTS THAT GUIDE PATIENT CARE, TODAY ANNOUNCED THAT ITS EXECUTIVE MANAGEMENT IS SCHEDULED TO PRESENT A COMPANY OVERVIEW AT THE 2026 JEFFERIES GLOBAL HEALTHCARE CONFERENCE ON WEDNESDAY, JUNE 3, 2026, AT 1:20 P.M. EASTERN TIME.

CASTLE BIOSCIENCES TO PRESENT AT THE 2026 JEFFERIES GLOBAL HEALTHCARE CONFERENCE

THIS MARKS THE FIFTH MEDTECH BREAKTHROUGH AWARD THAT CASTLE HAS EARNED FOR ITS INNOVATIVE TESTING SOLUTIONS FRIENDSWOOD, TEXAS, MAY 12, 2026 /PRNEWSWIRE/ -- CASTLE BIOSCIENCES, INC. (NASDAQ: CSTL), A COMPANY IMPROVING HEALTH THROUGH INNOVATIVE TESTS THAT GUIDE PATIENT CARE, TODAY ANNOUNCED THAT ITS ADVANCEAD-TX TEST HAS BEEN SELECTED AS THE WINNER OF THE "GENOMICS INNOVATION AWARD" IN THE 10TH ANNUAL MEDTECH BREAKTHROUGH AWARDS PROGRAM, WHICH RECOGNIZES COMPANIES DRIVING MEANINGFUL PROGRESS AND IMPROVING PATIENT CARE ACROSS THE GLOBAL HEALTH AND MEDICAL TECHNOLOGY INDUSTRY. ADVANCEAD-TX IS CASTLE'S CLINICALLY VALIDATED GENE EXPRESSION PROFILE (GEP) TEST DESIGNED TO GUIDE SYSTEMIC TREATMENT DECISION MAKING IN PATIENTS 12 AND OLDER WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS (AD).

CASTLE BIOSCIENCES' ADVANCEAD-TX TEST RECEIVES 2026 MEDTECH BREAKTHROUGH AWARD FOR GENOMICS INNOVATION

DELIVERED Q1 2026 REVENUE OF $83.7 MILLION Q1 2026 TOTAL TEST REPORTS FOR OUR CORE REVENUE DRIVERS (DECISIONDX  -MELANOMA, TISSUECYPHER  ) INCREASED 36% OVER Q1 2025 RAISING FULL-YEAR 2026 REVENUE GUIDANCE TO $345-355 MILLION FROM $340-350 MILLION CONFERENCE CALL AND WEBCAST TODAY AT 4:30 P.M. ET FRIENDSWOOD, TEXAS, MAY 6, 2026 /PRNEWSWIRE/ --CASTLE BIOSCIENCES, INC. (NASDAQ: CSTL), A COMPANY IMPROVING HEALTH THROUGH INNOVATIVE TESTS THAT GUIDE PATIENT CARE, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH31, 2026.

Castle Biosciences, Inc.

CSTL

Price

Financial Reports

No items found.

Press Releases

Castle Biosciences, Inc.

CSTL.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

CSTL